Parliament can bring all stakeholders around the table to work on Alzheimer’s, says MEP Jerković
Lilly is supportive of the European Parliament taking steps to address Alzheimer's disease (AD), a condition affecting 7 million EU citizens, by integrating it into the EU’s broader health strategies. This initiative aims to help healthcare systems overcome barriers to early and accurate diagnosis, ensure accessible care, and overcome ongoing stigma that those with AD face.
Advancements in blood biomarkers for diagnosing AD offer hope for less invasive and cost-effective solutions to AD management. However, barriers to the widespread use of biomarker testing persist, including the need for standardization, addressing cost and accessibility issues, and minimizing the psychological and financial impacts of false results.
As new blood-based diagnostic tools and therapies emerge, policymakers and researchers aim to bridge gaps in care and improve outcomes for those affected by AD across Europe. In this final article from an independent series supported by Lilly, several advocates rally for increased EU funding for AD research, focusing on early detection and diagnosis to make this a reality.
Tags in this Article:
No categories
Related articles
‘It’s a very individual disease’, Alzheimer’s activist urges policymakers to boost...
A diagnosis of Alzheimer’s disease (AD) can be devastating, both for the individual and their family. While AD impacts each person differently, one thing that all patients can benefit from is having more time to understand what changes lie ahead, and plan for their future. At Lilly, we recognize that access to early and accurate diagnosis is essential to connecting patients and their families to the care and support they need.
BE PIONEERING: The benefits of unlocking the value of diagnostic innovation in...
There is an urgent need to improve access to new innovations in the diagnosis and treatment of Alzheimer's disease. Embracing breakthroughs such as blood-based biomarker testing, has the potential to transform timely, accurate diagnosis for the benefit of patients and healthcare systems.
Rewriting Alzheimer’s future together – a call to action for G7 countries
While treatments for Alzheimer’s disease have advanced dramatically, greater political will is needed to harness their potential and bring innovation to the fore. Leaders have a crucial opportunity to collaborate, change the current discourse around Alzheimer’s disease and usher in a new era – one of support, understanding and hope.